 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Bioverativ
BIVV
conference date: February 14, 2018 @ 5:00 AM Pacific Time
Bioverativ Target Raised on 10-K Data [Seeking Alpha, March 27, 2017]
Bioverativ Should have a Strong Launch [January 10, 2017 @ Seeking Alpha]
Note: BIVV started trading on February 1, 2017.
2017 |
|||
May 4, 2017 |
August 3, 2017 |
Oct. 27, 2017 |
Feb. 14, 2017 |
Bioverativ (BIVV) is a commercial-stage biotechnology company specializing in hemophilia therapies and developing therapies for other blood disorders. It was spun off from Biogen (BIIB).
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| BIND |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MYL. |
| NVDA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2017 William P. Meyers